TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01494116

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 900 mL of 0.9% Normal Saline
Description: The intervention consists of the administration of 900 mL of Normal Saline to the model using the Disconnection- Reconnection method of manual fluid resuscitation. All syringes (syringe size based on study arm) will be prepared by research staff following subject randomization. Each subject will take the prepared syringes, and sequentially administer them to the model by 1. Selecting and connecting a fluid-filled syringe to the catheter extension set to permit fluid administration 2. Manually administering the fluid to the model by depressing the syringe plunger 3. Disconnecting and discarding the empty syringe 4. Repeating steps 1-3 as fast as possible until all 900 mL has been administered.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 900 mL of 0.9% Normal Saline
Description: The intervention consists of the administration of 900 mL of Normal Saline to the model using the Disconnection- Reconnection method of manual fluid resuscitation. All syringes (syringe size based on study arm) will be prepared by research staff following subject randomization. Each subject will take the prepared syringes, and sequentially administer them to the model by 1. Selecting and connecting a fluid-filled syringe to the catheter extension set to permit fluid administration 2. Manually administering the fluid to the model by depressing the syringe plunger 3. Disconnecting and discarding the empty syringe 4. Repeating steps 1-3 as fast as possible until all 900 mL has been administered.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 900 mL of 0.9% Normal Saline
Description: The intervention consists of the administration of 900 mL of Normal Saline to the model using the Disconnection- Reconnection method of manual fluid resuscitation. All syringes (syringe size based on study arm) will be prepared by research staff following subject randomization. Each subject will take the prepared syringes, and sequentially administer them to the model by 1. Selecting and connecting a fluid-filled syringe to the catheter extension set to permit fluid administration 2. Manually administering the fluid to the model by depressing the syringe plunger 3. Disconnecting and discarding the empty syringe 4. Repeating steps 1-3 as fast as possible until all 900 mL has been administered.
Study: NCT03938857

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl standard of care

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fentanyl
Description: Fentanyl standard of care

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine (0.5 mcg/kg + 0.2 mcg/kg/hr)
Study: NCT05746156

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: lymphatic mapping
Description: 1. Peritumoral injection of \[99mTc\]Tc-nanocolloid in 6-8 evenly distributed depots on both sides of the tumor, during investigation under anaesthesia. Number of depots depending on the size and localisation of the tumor.~2. Planair and SPECT/CT imaging van de abdomen/pelvis 3h and 12-24h after injection at the department of radiology and nucleair medicine.
Study: NCT03938857

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine (0.5 mcg/kg + 0.5 mcg/kg/hr)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexmedetomidine
Description: Dexmedetomidine (0.5 mcg/kg + 0.7 mcg/kg/hr)
Study: NCT01822782

Intervention type: BIOLOGICAL
Intervention: Bacteriological analysis of vaginal sample
Description: Bacteriological analysis of vaginal sample
Study: NCT01163929

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Paclitaxel:~80mg/m2 IV TRO 3 hours every 28 days for 4 cycles~Trastuzumab:~4mg/kg IV load dose (TRO 90) minutes followed by 2 mg/kg TRO 60 minutes every week for 18 weeks~Everolimus: 10mg PO daily 16-18 weeks
Study: NCT04738370

Intervention type: OTHER
Intervention: Sample collection
Description: Bloods +/- urine +/- vaginal swabs taken
Study: NCT01527058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 68Ga-BNOTA-PRGD2
Description: Cancer patients, single intravenous bolus injection of nearly 111 MBq 68Ga-NOTA-PRGD2 on day one of the treatment period, dynamic whole-body PET/CT for determination of effective dose, kinetics of 68Ga-BNOTA-PRGD2 in blood, organs, and tumors~Healthy volunteers, single intravenous bolus injection of nearly 111 MBq 68Ga-BNOTA-PRGD2 on day one of the treatment period, dynamic whole-body PET/CT for determination of effective dose, kinetics of 68Ga-BNOTA-PRGD2 in blood and organs
Study: NCT04600518

Intervention type: DEVICE
Intervention: nProfiler I Stomach Cancer Assay Kit
Description: nProfiler I Stomach Cancer Assay Kit (Novomics Co., Korea)
Study: NCT03803956

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Active PBMT
Description: The PBMT will be performed using the dose of 10J per diode, previously determined by a previous study and power output of 100 mW per diode, also previously determined. PBMT will be performed at nine different sites of the knee extensor muscles, six different sites of the knee flexor muscles and two different sites of the plantar flex muscles. As the cluster will be 5 diodes and 17 different sites will be irradiated, a total of 85 points will be irradiated in each lower limb, a total of 850 J of energy. The active PBMT will be performed before a progressive running test.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo PBMT
Description: The placebo PBMT will per performed using the dose of 0 J per diode. Placebo PBMT will be performed at nine different sites of the knee extensor muscles, six different sites of the knee flexor muscles and two different sites of the plantar flex muscles. As the cluster will be 5 diodes and 17 different sites will be irradiated, a total of 85 points will be irradiated in each lower limb, a total of 0 J of energy. To ensure blinding, the device emitted the same sound regardless of the programmed mode (active or placebo PBMT). The placebo PBMT will be performed before a progressive running test.
Study: NCT02360358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiscover
Description: two step procedure, week 0 and week1. Dosage depends on wound size.
Study: NCT00555165

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Telescope prosthesis
Description: Monocular implantation of the telescope prosthesis after cataract extraction
Study: NCT02360358

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: AS210
Description: two step procedure, week 0 and week1. Dosage depends on wound size.
Study: NCT00764465

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maraviroc
Description: 300 mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maraviroc
Description: 300 mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maraviroc
Description: 300 mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maraviroc
Description: 300 mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maraviroc
Description: 300 mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Maraviroc
Description: 300 mg BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosamprenavir
Description: 1400 mg BID, 700 mg BID or 1400 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosamprenavir
Description: 1400 mg BID, 700 mg BID or 1400 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosamprenavir
Description: 1400 mg BID, 700 mg BID or 1400 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosamprenavir
Description: 1400 mg BID, 700 mg BID or 1400 mg QD

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fosamprenavir
Description: 1400 mg BID, 700 mg BID or 1400 mg QD
Study: NCT01747954

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Bag Squeezing
Description: To perform the BS technique, we used a Protec® manual inflation bag with a flow of 10 L / min and 100% oxygen. A Commercial Medical® manometer was adapted between the orotracheal tube and the inflation bag to monitor the inflation pressure which was recommendedat 30 cmH2O for all children of the BS group. Initially we instilled at most 0.5 ml saline solution(SS) at 0.9% followed by 10 manual hyperinflation maneuvers interspersed with 10 vibrocompression maneuvers and as a last procedure, we performed an aspiration of the orotracheal tube airways and mouth. Between the aspirations the child was re-connected to the ventilator.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Thoracic vibrocompression
Description: To perform the TVC technique, we applied 10 vibrocompression maneuvers on the chest of the children during the expiratory phase of the respiratory cycle, on each of the lateral decubitus position, totaling 20 maneuvers, followed by aspiration in the dorsal decubitus position. All measurements in both study groups were performed with the child connected to the ventilator. Before starting the maneuver BS or TVC the child received an increase of 20% fraction of inspired oxygen (FiO2) from what was received previously in MV and after data collection FiO2 returned to baseline values.
Study: NCT03487471

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Real-time elastography
Description: Breast ultrasound with real-time elastography

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Shear wave elastography
Description: Breast ultrasound with shear wave elastography
Study: NCT02816606

Intervention type: PROCEDURE
Intervention: Flexible reamers
Description: These reamers allow creation of the femoral tunnel to be made in reduced knee flexion and potentially maximise tunnel length

Intervention type: PROCEDURE
Intervention: 70-degree arthroscope
Description: Using this arthroscope (rather than the more traditional 30-degree) gives improved visualisation of the femoral and tibial footprints. This may translate into better positioning of the tunnel within these regions
Study: NCT01564537

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ixazomib
Description: Ixazomib capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lenalidomide
Description: Lenalidomide capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Dexamethasone
Description: Dexamethasone tablets

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Ixazomib placebo-matching capsules
Study: NCT03856827

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IW-6463
Description: IW-6463 Tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Matching Placebo
Description: Matching Placebo Tablet
Study: NCT03082092

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone Sodium Succinate
Description: single intravenous dose of 125mg methylprednisolone diluted in 2.1ml of diluent given on induction of total knee replacement

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 0.9% intravenous saline (2.1ml) intravenously on induction of total knee replacement
Study: NCT02524158

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Yoga Therapy for CLBP
Description: Classes begin with a few minutes of simple seated breathing exercises. Depending on their mobility, participants can sit either on the floor or on a chair. This is followed by gentle warm-up stretches. Participants are then led through a series of standing postures, seated postures and floor postures. The difficulty of the poses will gradually increase over the duration of the 12 weeks, and appropriate modifications are offered to participants whenever needed. Deep and rhythmic breathing will be emphasized throughout. Each class will end with a supine resting pose.
Study: NCT03536832

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cesarean Section with Vicryl
Description: Pfnannenstiel incision will be done under general or spinal anaesthesia. The abdomen will be opened and fetus and plasenta will be delivered. Then abdomen will be closed. Skin will be closed with Vicryl.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cesarean Section with Prolen
Description: Pfnannenstiel incision will be done under general or spinal anaesthesia. The abdomen will be opened and fetus and plasenta will be delivered. Then abdomen will be closed. Skin will be closed with prolen.
Study: NCT01439594

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MGH OFDI Imaging
Description: Imaging of Esophagus with OFDI system
Study: NCT03100058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: LIK066 will be supplied in different doses as tablets to be taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: LIK066 will be supplied in different doses as tablets to be taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: LIK066 will be supplied in different doses as tablets to be taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: LIK066 will be supplied in different doses as tablets to be taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: LIK066 will be supplied in different doses as tablets to be taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: LIK066 will be supplied in different doses as tablets to be taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: LIK066 will be supplied in different doses as tablets to be taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: LIK066 will be supplied in different doses as tablets to be taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: LIK066 will be supplied in different doses as tablets to be taken orally.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: LIK066 will be supplied in different doses as tablets to be taken orally.
Study: NCT03395197

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Talazoparib with enzalutamide
Description: Talazoparib 0.5 mg/day plus enzalutamide 160mg/day

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo with enzalutamide
Description: Placebo plus enzalutamide 160 mg/day
Study: NCT04555694

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclosporine
Description: Used to increase tear production in patients who have dry eye caused by inflammation
Study: NCT03100058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LIK066
Description: LIK066 will be supplied in different doses as tablets to be taken orally.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT04035239

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BGS goggles
Description: BGS goggles use for 3-6 weeks
Study: NCT00004883

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT00974922

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren
Description: 150 mg once daily for 2 weeks, then titrated to 300 mg once daily for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aliskiren
Description: 150 mg once daily for 2 weeks, then titrated to 300 mg once daily for 4 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: 3000 I.U. once daily for 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: 3000 I.U. once daily for 6 weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo for two weeks

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo for two weeks
Study: NCT02738710

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: transumbilical incision
Description: incision within umbilicus

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Infra umbilical incision
Description: incision about 1 cm below umbilicus
Study: NCT00929851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHF1535
Description: Beclomethasone dipropionate 100 µg plus formoterol fumarate 6 µg/per metered dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Formoterol fumarate
Description: Formoterol fumarate 12 µg per metered dose
Study: NCT01342601

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ect4allergy Nasal Spray (ANS01) and Eye Drops (AAT01)
Description: Comparison of ANS01 and AAT01 with placebo

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo products
Description: Nasal Spray and Eye drops without Ectoin
Study: NCT03590210

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Cycle 1 to 16 1.5mg/m² IV over 24 hours, q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trabectedin
Description: Cycle 1 to 16 1.5mg/m² IV over 24 hours, q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Cycle 2 to 16 240 mg IV over 30 minutes, q3w

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Cycle 2 to 16 240 mg IV over 30 minutes, q3w
Study: NCT02398864

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EBUS with TBNA
Description: endobronchial ultrasound (EBUS) with transbronchial needle aspiration (TBNA)
Study: NCT02692443

Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging
Description: Brain MRI without Contrast

Intervention type: DEVICE
Intervention: Magnetic Resonance Imaging
Description: Brain MRI without Contrast

Intervention type: BEHAVIORAL
Intervention: Neurodevelopmental Testing
Description: Validated battery of neurodevelopmental and psychological tests.

Intervention type: BEHAVIORAL
Intervention: Neurodevelopmental Testing
Description: Validated battery of neurodevelopmental and psychological tests.
Study: NCT03575377

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Disposal Aid
Description: Deterra® drug deactivation system
Study: NCT02449850

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food intervention
Description: Intervention; systematic introduction of egg, milk, wheat and peanut by 4 months of age

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Food intervention
Description: Intervention; systematic introduction of egg, milk, wheat and peanut by 4 months of age

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin care
Description: Bath with bath-oil aim and Ceridal face cream for least 5 times/ week from 0.5-9 months of age.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skin care
Description: Bath with bath-oil aim and Ceridal face cream for least 5 times/ week from 0.5-9 months of age.
Study: NCT05256186

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Basketball Pre-injury Attack program
Description: The intervention had a total duration of 24 weeks, with 3 sessions per week (before starting training) with a total duration of 12 to 15 minutes per session. Each session consisted of 8 exercises with a load of 2 to 3 series between 6 and 12 repetitions; and with a rest at the end of each series of \<60 seconds.
Study: NCT04827498

Intervention type: DIAGNOSTIC_TEST
Intervention: Invasive coronary endothelium-dependent and non-endothelium-dependent physiological assessment
Description: Coronary hemodynamics and vessel anatomical measures obtained during adenosine and acetylcholine evaluation with a dedicated physiology wire
Study: NCT01470092

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tibolone
Description: Subjects will take 2.5mg of oral Tibolone daily for the duration of the 12 week trial either alone or in adjunct to currently prescribed antidepressant medication.
Study: NCT00910676

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diprosone
Description: * Start of treatment: as soon as the EGF-R inhibitors treatment begins~* Application: On the body area susceptible to be affected by folliculitis, once a day, in the evening~* Dosage: Quantity corresponded to around 2 tubes of 30 grams a week on the face, the chest and upper side of the back. There is no maximum dosage.~* Period of treatment: 8 weeks
Study: NCT02557763

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxford unicompartmental knee arthroplasty
Description: The patients with medial osteoarthritis knee with patellofemoral arthritis were performed surgery and applied Oxford unicompartmental knee arthroplasty.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Oxford unicompartmental knee arthroplasty
Description: The patients with medial osteoarthritis knee with patellofemoral arthritis were performed surgery and applied Oxford unicompartmental knee arthroplasty.
Study: NCT03591510

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midostaurin
Description: midostaurin 30mg/m2 bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30mg/m2/day on D1-D5 of Block 2 FLADx

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Part 1:~2000mg/m2/day D1 to D5 of Block 2 FLADx 1000mg/m2 every 12 hours D1 to D3 Block 3 HAM 3000mg/m2 every 12 hours D1 to D3 Block 4 HA3E 3000mg/m2 every 12 hours D1 to D3 Block 5 HIDAC~Part 2:~1000mg/m2 every 12 hours D1 to D3 Block 2 HAM 3000mg/m2 every 12 hours D1 to D3 Block 3 HA3E 1000mg/m2 every 12 hours D1 to D3 Block 4 HAM 3000mg/m2 every 12 hours D1 to D3 Block 5 HIDAC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daunorubicin or idarubicin
Description: daunorubicin 60 mg/m2/day OR idarubicin 12mg/m2/day On D2, D4, D6 of Block 2 FLADx

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Description: 10mg/m2/day D3 and D4

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100mg/m2/day D1 to D5
Study: NCT00934024

Intervention type: DRUG
Group type: OTHER
Intervention: varenicline
Description: Participants will be treated with a standard course of varenicline, 0.5 mg 1 tablet every day for 3 days, then 0.5 mg 1 tab twice a day for four days, and 1 mg 1 tablet twice a day for three months.

Intervention type: DRUG
Group type: OTHER
Intervention: varenicline
Description: Participants will be treated with a standard course of varenicline, 0.5 mg 1 tablet every day for 3 days, then 0.5 mg 1 tab twice a day for four days, and 1 mg 1 tablet twice a day for three months.